Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
766.66
-24.15 (-3.05%)
At close: Mar 3, 2026, 4:00 PM EST
767.20
+0.54 (0.07%)
After-hours: Mar 3, 2026, 5:36 PM EST
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for Regeneron Pharmaceuticals stock have an average target of 815.04, with a low estimate of 587 and a high estimate of 1,057. The average target predicts an increase of 6.31% from the current stock price of 766.66.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock from 23 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 8 | 8 | 9 | 9 | 9 |
| Buy | 9 | 8 | 7 | 8 | 7 | 7 |
| Hold | 5 | 6 | 7 | 7 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 23 | 23 | 25 | 23 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $745 → $765 | Hold | Maintains | $745 → $765 | -0.22% | Mar 2, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $865 → $975 | Strong Buy | Maintains | $865 → $975 | +27.18% | Feb 9, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $850 → $950 | Buy | Maintains | $850 → $950 | +23.91% | Feb 2, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $750 → $865 | Buy | Reiterates | $750 → $865 | +12.83% | Feb 2, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $768 → $769 | Hold | Maintains | $768 → $769 | +0.31% | Feb 2, 2026 |
Financial Forecast
Revenue This Year
16.02B
from 14.34B
Increased by 11.69%
Revenue Next Year
17.64B
from 16.02B
Increased by 10.12%
EPS This Year
46.46
from 41.48
Increased by 12.00%
EPS Next Year
54.70
from 46.46
Increased by 17.75%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 18.4B | 19.5B | |||
| Avg | 16.0B | 17.6B | |||
| Low | 14.4B | 15.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.0% | 21.4% | |||
| Avg | 11.7% | 10.1% | |||
| Low | 0.3% | -1.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 61.62 | 66.32 | |||
| Avg | 46.46 | 54.70 | |||
| Low | 36.39 | 45.43 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 48.6% | 42.8% | |||
| Avg | 12.0% | 17.7% | |||
| Low | -12.3% | -2.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.